Comorbidity After Gastric Bypass
- Conditions
- Severe Obesity
- Interventions
- Procedure: Gastric bypass
- Registration Number
- NCT02710786
- Lead Sponsor
- Uppsala University
- Brief Summary
To evaluate effect on comorbid disease and weight loss in the long-term (\>five years) after Roux-en-Y gastric bypass (RYGB) surgery for severe obesity.
- Detailed Description
Individuals with severe obesity frequently have comorbid diseases, e.g. diabetes, hypertension, hyperlipidemia, and sleep apnea. We will study the remission rate and weight loss in the long-term (10 years) after Roux-en-Y gastric bypass (RYGB) surgery in a nationwide large group of patients.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 25000
- Registered individuals in Scandinavian Obesity Surgery Registry (SOReg) having had gastric bypass
- All other operations
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Gastric bypass Gastric bypass Patients undergoing gastric bypass
- Primary Outcome Measures
Name Time Method Change in comorbid conditions, as defined by use of pharmacological treatment 10 years Remission of diabetes mellitus, hypertension, dyslipidemia, and depression as defined by use of pharmacological treatment, and sleep apnea as defined by use of CPAP. Data will be collected from SOReg.
- Secondary Outcome Measures
Name Time Method Weight loss 10 years Peroperative weight (in kg) minus current weight (in kg)
BMI loss 10 years Peroperative BMI minus current BMI. Weight and height will be combined to report BMI in kg/m\^2.
Number of patients with pathological laboratory data (corresponding to the studied comorbid conditions) 10 years Glucose, HbA1c, LDL, HDL, triglycerides, and blood pressure
Trial Locations
- Locations (1)
Uppsala University
🇸🇪Uppsala, Sweden